Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator

xlomafota13 shared this article with you from Inoreader Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator Via American Journal of Cancer Research Am J Cancer Res. 2021 Jul 15;11(7):3445-3460. eCollection 2021. ABSTRACT Paclitaxel is a widely used anti-tumor chemotherapeutic drug. Solvent-based paclitaxel causes bone marrow suppression, allergic reactions, neurotoxicity and systemic toxicity, which are associated with non-specific cytotoxicity and side effects of fat-soluble solvents. Studies have explored various new nano-drug strategies of paclitaxel, including nanoparticle albumin-bound paclitaxel (nab-paclitaxel) to improve the water solubility and safety of paclitaxel. Nab-paclitaxel is a targeted solvent-free formulation that inhibits microtubule depolymerization to anticancer. It is easily taken up by tumor and immune cells owing to the nano-scaled size and superior biocompatibility. The internalized nab-paclitaxel exhibits significant immunostimulatory activities to promote cancer-immunity cycle. The aim of this study was to explore the synergistic effect of nab-paclitaxe l in tumor antigen presentation, T cell activation, reversing the immunosuppressive pattern of tumor microenvironment (TME), and the synergistic effect with cytotoxic lymphocytes (CTLs) in clearance of tumor cells. The effects of nab-paclitaxel on modulation of cancer-immunity cycle, provides potential avenues for combined therapeutic rationale to improve efficacy of immunotherapy. PMID:34354854 | PMC:PMC8332864 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.